Cancer Australia launches Lung Cancer Framework

  • Cancer Australia launches Lung Cancer Framework

Cancer Australia launches Lung Cancer Framework

In another study, the combination of Bristol-Myers Squibb's Opdivo and Yervoy worked better than chemo alone for delaying the time until cancer worsened in advanced lung cancer patients whose tumors have many gene flaws, as almost half do, AP reported.

Two promising new studies suggest combining Immune Therapy drugs with chemotherapy may improve survival.

Combining an immunotherapy drug with chemotherapy almost doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed.

Results of the study are expected to change how 70,000 patients are treated each year in the United States whose lung cancer has already spread by the time it is found, according to AP. He said that tumor cells were like bags of hidden proteins that, if exposed, the immune system could use as targets to find and attack cancer.

Gandhi said chemotherapy alone had only a "modest benefit", and could add only a few months of life, with most patients surviving about a year or less. Chemotherapy has limitations. Immunotherapy has the ability to cure.

The other, auto T therapy, genetically reprograms a patient's immune T-cells to find and destroy cancer. The most common side effects were nausea, anemia and fatigue and in both groups about 65% of patients experienced severe side effects. The immune-activating drug was a checkpoint inhibitor called pembrolizumab, or Keytruda, made by Merck, which paid for the study.

'I've never seen such a big paradigm shift as we're seeing with immunotherapy, ' he said. The report shows that 3.8 million people were diagnosed with cancer each year and more than 2.2 million patients died.

For non-squamous non-small cell lung cancer patients, median survival with chemotherapy alone is somewhere around 11 or 12 months, he said. I lead the Yale lung team. These drugs are very, very interesting.

Cancer patients should be given immunotherapy as the first line of treatment following the results of "game-changing" trials, charities say.